Jason J Rose1,2, Mehdi Nouraie1,2, Marc C Gauthier2, Anthony F Pizon3,4, Melissa I Saul5, Michael P Donahoe2,5, Mark T Gladwin1,5. 1. Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA. 2. Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA. 3. Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA. 4. Division of Medical Toxicology, Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA. 5. Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Abstract
OBJECTIVES: Carbon monoxide poisoning affects 50,000 per year in the United States alone. Mortality is approximately 3%, and up to 40% of survivors suffer from permanent neurocognitive and affective deficits. Hyperbaric oxygen therapy has shown benefit on reducing the long-term neurologic sequelae of carbon monoxide poisoning but has not demonstrated improved survival. The objective of this study is to assess the efficacy of hyperbaric oxygen for acute and long-term mortality in carbon monoxide poisoning using a large clinical databank. DESIGN: Retrospective analysis. SETTING: University of Pittsburgh Medical Center healthcare system (Pittsburgh, PA). PATIENTS: One-thousand ninety-nine unique encounters of adult patients with carbon monoxide poisoning. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Baseline demographics, laboratory values, hospital charge transactions, discharge disposition, and clinical information from charting were obtained from the electronic medical record. In propensity-adjusted analysis, hyperbaric oxygen therapy was associated with a reduction in inpatient mortality (absolute risk reduction, 2.1% [3.7-0.9%]; p = 0.001) and a reduction in 1-year mortality (absolute risk reduction, 2.1% [3.8-0.4%]; p = 0.013). CONCLUSIONS: These data demonstrate that hyperbaric oxygen is associated with reduced acute and reduced 1-year mortality. Further studies are needed on the mortality effects of hyperbaric oxygen therapy in carbon monoxide poisoning.
OBJECTIVES:Carbon monoxidepoisoning affects 50,000 per year in the United States alone. Mortality is approximately 3%, and up to 40% of survivors suffer from permanent neurocognitive and affective deficits. Hyperbaric oxygen therapy has shown benefit on reducing the long-term neurologic sequelae of carbon monoxidepoisoning but has not demonstrated improved survival. The objective of this study is to assess the efficacy of hyperbaric oxygen for acute and long-term mortality in carbon monoxidepoisoning using a large clinical databank. DESIGN: Retrospective analysis. SETTING: University of Pittsburgh Medical Center healthcare system (Pittsburgh, PA). PATIENTS: One-thousand ninety-nine unique encounters of adult patients with carbon monoxidepoisoning. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Baseline demographics, laboratory values, hospital charge transactions, discharge disposition, and clinical information from charting were obtained from the electronic medical record. In propensity-adjusted analysis, hyperbaric oxygen therapy was associated with a reduction in inpatient mortality (absolute risk reduction, 2.1% [3.7-0.9%]; p = 0.001) and a reduction in 1-year mortality (absolute risk reduction, 2.1% [3.8-0.4%]; p = 0.013). CONCLUSIONS: These data demonstrate that hyperbaric oxygen is associated with reduced acute and reduced 1-year mortality. Further studies are needed on the mortality effects of hyperbaric oxygen therapy in carbon monoxidepoisoning.
Authors: Lindell K Weaver; Ramona O Hopkins; Karen J Chan; Susan Churchill; C Gregory Elliott; Terry P Clemmer; James F Orme; Frank O Thomas; Alan H Morris Journal: N Engl J Med Date: 2002-10-03 Impact factor: 91.245
Authors: Neil B Hampson; Claude A Piantadosi; Stephen R Thom; Lindell K Weaver Journal: Am J Respir Crit Care Med Date: 2012-10-18 Impact factor: 21.405
Authors: Satoshi Fukuda; Yosuke Niimi; Clark R Andersen; Ennert R Manyeza; Jose D Rojas; Donald S Prough; Perenlei Enkhbaatar Journal: Biochem Biophys Res Commun Date: 2020-03-18 Impact factor: 3.575
Authors: David H Jang; Sarah Piel; John C Greenwood; Matthew Kelly; Vanessa M Mazandi; Abhay Ranganathan; Yuxi Lin; Jonathan Starr; Thomas Hallowell; Frances S Shofer; Wesley B Baker; Alec Lafontant; Kristen Andersen; Johannes K Ehinger; Todd J Kilbaugh Journal: Clin Toxicol (Phila) Date: 2021-02-02 Impact factor: 4.467
Authors: David H Jang; Sarah Piel; John C Greenwood; Johannes K Ehinger; Todd J Kilbaugh Journal: Am J Physiol Cell Physiol Date: 2021-06-16 Impact factor: 5.282